Baillie Gifford Trims Vertex Pharmaceuticals Stake

Institutional investor reduces position in biotech firm by 2.9% in Q4

Apr. 14, 2026 at 7:35am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, interlocking metal gears and machinery, conveying the complex financial infrastructure that supports the biotech industry.A visual metaphor for the behind-the-scenes financial mechanisms driving innovation in the biotech sector.Boston Today

Baillie Gifford & Co., a major institutional investor, trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.9% in the fourth quarter, according to a recent SEC filing. The fund still owns 201,088 shares of the pharmaceutical company's stock, valued at approximately $91.17 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases, particularly cystic fibrosis. Changes in ownership by major institutional investors can provide insights into market sentiment and future performance expectations for the company.

The details

According to the 13F filing, Baillie Gifford sold 5,968 shares of Vertex Pharmaceuticals during the fourth quarter. The firm now owns about 0.08% of the company's outstanding shares. Other major institutional investors in Vertex include Mitsubishi UFJ Asset Management, Danske Bank, and Advisory Resource Group.

  • Baillie Gifford filed the 13F report disclosing the ownership change in the fourth quarter of 2025.

The players

Baillie Gifford & Co.

A major institutional investor and asset management firm based in the United Kingdom.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing treatments for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

This filing indicates that one of Vertex Pharmaceuticals' largest institutional investors has slightly reduced its stake in the company, though it still maintains a sizable position. The move could signal a shift in market sentiment or portfolio rebalancing, but does not necessarily reflect any major concerns about Vertex's long-term prospects.